QPharma AB
ABActiveOrg 5564995081Agneslundsvägen 27, 212 15 MalmöManufacture of pharmaceutical preparations· NACE 2120Est. 1994 · 31 years old278 employees
Loading company…
Overview
QPharma AB is a Swedish AB based in Malmö, operating in the Manufacture of pharmaceutical preparations sector. Incorporated in 1994, the company has 278 employees and reported revenue of SEK 557.2m in its latest annual filing.
Revenue 2025
557.2M SEK
−22% vs 2024
EBITDA margin
1.8 %
−90% vs 2024
Net profit 2025
-4.5M SEK
-114% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
66.7 %
StrongAmong the 40% highest rated companies in the industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
2.2×
AverageAround the average of companies in the same industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
-0.8 %
WeakAmong the 30% lowest rated companies in the industry
20212025
EBITDA — year on year
SEK millionsKey figures
Annual report 2025| Revenue | 557.2M SEK | -22% |
| EBITDA | 9.9M SEK | -90% |
| Net profit | -4.5M SEK | -114% |
| Total assets | 590.5M SEK | -16% |
| Equity | 393.8M SEK | -1% |
| Employees | 278 | — |
Company information
Legal name
QPharma AB
Org number
5564995081
Legal form
Aktiebolag
NACE code
Founded
30 November 1994 · 31 years
Share capital
SEK 10,000,000
Employees
278 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget har till föremål för sin verksamhet att bedriva forskning och utveckling inom området för mediciniska, diagnostiska, farmaceutiska och kemisk-tekniska produkter, att förvärva och upplåta licenser och agenturer inom området, att idka därmed förenlig verksamhet samt att idka finansiell verksamhet, dock ej sådan verksamhet som avses i lag om bankrörelse eller lag om kreditaktiebolag. Bolaget har vidare till föremål för sin verksamhet att äga och förvalta värdepapper samt idka därmed förenlig verksamhet.
(no translation available)
Contact
Address
Agneslundsvägen 27, 212 15 Malmö
Phone
+4640361800
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), QPharma AB reported revenue of SEK 557.2m, a decrease of 22% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net loss of SEK 4.5m, and the EBITDA margin stood at 1.8%.
At the end of 2025, equity financed 66.7% of the balance sheet, and current assets covered short-term debt 2.2 times.
Financials
Revenue
SEK millionsEBITDA
SEK millionsIncome statement
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 557,166 | 712,158 | 633,791 | 609,905 | 477,861 |
| Staff expenses | -233,022 | -262,906 | — | — | — |
| EBITDA | 9,895 | 95,152 | 8,160 | 44,658 | 48,810 |
| Depreciation & amort. | -32,662 | -24,600 | -26,304 | -22,010 | -16,846 |
| EBIT | -22,767 | 70,552 | -18,144 | 22,648 | 31,964 |
| Net financials | -14,491 | 234 | -5,408 | -8,572 | -4,965 |
| Profit before tax | -4,758 | 41,488 | 3,392 | 14,955 | 16,510 |
| Tax | 215 | -9,187 | -2,547 | -2,644 | -3,697 |
| Net profit | -4,543 | 32,301 | 845 | 12,311 | 12,813 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 590,530 | 701,833 | 637,026 | 546,972 | 455,704 |
| Equity | 393,773 | 398,316 | 366,015 | 273,490 | 171,950 |
| Long-term debt | 4,077 | 34,300 | 0 | 0 | 111,020 |
| Short-term debt | 142,694 | 185,434 | 217,313 | 193,734 | 94,271 |
| Total debt | 146,771 | 219,734 | 217,313 | 193,734 | 205,291 |
Financial ratios
5-year trendEBITDA margin
1.8 %
20212025
Equity ratio
66.7 %
StrongAmong the 40% highest rated companies in the industry
20212025
Return on equity
-1.2 %
WeakAmong the 30% lowest rated companies in the industry
20212025
Net profit margin
-0.8 %
WeakAmong the 30% lowest rated companies in the industry
20212025
Asset turnover
0.94×
AverageAround the average of companies in the same industry
20212025
Debt / equity
0.50×
StrongAmong the 30% highest rated companies in the industry
20212025
Sector performance
28 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginWeak
Among the 30% lowest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginWeak
Among the 30% lowest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginWeak
Among the 30% lowest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Weak
Among the 30% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Weak
Among the 30% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Weak
Among the 30% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Weak
Among the 30% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioWeak
Among the 30% lowest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioAverage
Around the average of companies in the same industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioWeak
Among the 30% lowest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery weak
Among the 10% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery strong
Among the 20% highest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalWeak
Among the 40% lowest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioVery weak
Among the 10% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioStrong
Among the 40% highest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioStrong
Among the 30% highest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityStrong
Among the 30% highest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityStrong
Among the 40% highest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtWeak
Among the 30% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtWeak
Among the 40% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageWeak
Among the 30% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery weak
Among the 10% lowest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginWeak
Among the 30% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverAverage
Around the average of companies in the same industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverVery strong
Among the 20% highest rated companies in the industry
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Equity to contributed capitalStrong
Among the 30% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityWeak
Among the 40% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery strong
Among the 20% highest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
FH Chief Executive Officer | Chief Executive Officer | 2025 |
ES Chief Auditor | Chief Auditor | 2026 |
Former (4)
KS Chief Executive Officer | Chief Executive Officer | 2020 – 2025 |
OC Chief Auditor | Chief Auditor | 2020 – 2026 |
ND Chief Executive Officer | Chief Executive Officer | 2020 – 2020 |
SJ Chief Auditor | Chief Auditor | 2020 – 2020 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
CS Deputy Board Member | Deputy Board Member | 2025 |
FH Chairman | Chairman | 2025 |
JE Board of Directors | Board of Directors | 2026 |
EA Board of Directors | Board of Directors | 2020 |
BN Board of Directors | Board of Directors | 2025 |
JX Board of Directors | Board of Directors | 2025 |
Former (6)
KS Chairman | Chairman | 2022 – 2025 |
SJ Board of Directors | Board of Directors | 2020 – 2025 |
UK Board of Directors | Board of Directors | 2020 – 2020 |
HS Chairman | Chairman | 2020 – 2022 |
CF Board of Directors | Board of Directors | 2020 – 2025 |
MS Board of Directors | Board of Directors | 2022 – 2024 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Sever Life Science B.V.
QPharma AB Board network connections
Board members of QPharma AB also hold positions in 158 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Emilie Sofia Nord | Chief Auditor | 85 companiesMany roles |
| Ove Christofer Hultén | Chief Auditor | 46 companiesMany roles |
| Sven Jakob Tenselius | Chief Auditor | 14 companiesMany roles |
| Nils David Segerberg | Chief Executive Officer | 5 companies |
| Sten Jakob Hedén | Board of Directors | 3 companies |
| Fredrik Hultenius | Chief Executive Officer | 2 companies |
| Bengt Niklas Fredrik Ellerström | Board of Directors | 2 companies |
| Hans Schram | Chairman | 1 company |
Frequently asked questions
What is the Org number of QPharma AB?
QPharma AB is registered with Bolagsverket / SCB under Org 5564995081.
What is the revenue of QPharma AB?
QPharma AB reported revenue of SEK 557.2m in 2025.
How many employees does QPharma AB have?
QPharma AB employs 278 people as of the latest annual report.
Who is the CEO of QPharma AB?
Fredrik Hultenius is the CEO of QPharma AB, in role since 2025.
Who is the chairman of QPharma AB?
Fredrik Hultenius chairs the board of QPharma AB, in role since 2025.
Where is QPharma AB headquartered?
QPharma AB's registered address is Agneslundsvägen 27.